Merck To Get Chronic Cough P2X3 Inhibitor Candidate With Afferent Buy
Executive Summary
A candidate for chronic cough is one of the assets Merck & Co. will get by buying P2X3 inhibitor specialist Afferent Pharmaceuticals Inc, a US-based biotech focusing on chronic pain therapies caused when certain nerves become hypersensitive.
You may also be interested in...
Merck's Gefapixant CRL Dashes Hopes For Another Near-Term Growth Driver
The US FDA issued a complete response letter for the P2X3 receptor antagonist for the treatment of refractory chronic cough, requesting more efficacy data.
Merck & Co's Gefapixant Cuts Chronic Cough in Phase III
New data puts Merck & Co's P2X3 receptor antagonist ahead of the field but Bellus Health's rival in the class may benefit from issues over taste alteration with gefapixant.
Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.